Company / Operating Cash Flow
Spyre Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$169.3M
FY2025
5-year range
-$169.3M / -$53.7M
FY2021-FY2025
Trend
-7.5%
vs FY2024
Sector context
#156 of 216
Health Care
What the data says
At -$169M, Spyre Therapeutics, Inc.'s operating cash flow ranks #156 of 216 in the Health Care sector. Operating Cash Flow has declined for 7 consecutive years, from -$19M in FY2018 to -$169M in FY2025.
Based on SEC 10-K filings.
-$169M in FY2025.
Declined from -$100M to -$169M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#156 of 216 in Health CareTop 72% of 216This company -$169.3M Sector average $658.7M
▼
-125.7% below sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s operating cash flow has declined for 7 consecutive years.
- In FY2025, operating cash flow decreased 7.5% year-over-year.
- Ranks #156 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$169.3M | -7.5% |
| FY2024 | -$157.4M | -57.6% |
| FY2023 | -$99.9M | -31.9% |
| FY2022 | -$75.8M | -41.1% |
| FY2021 | -$53.7M | -66.9% |
| FY2020 | -$32.2M | -30.8% |
| FY2019 | -$24.6M | -30.7% |
| FY2018 | -$18.8M | +23.5% |
| FY2017 | -$24.6M | -30.7% |
| FY2016 | -$18.8M | -71.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026